CA3008015A1 — Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2017-07-13 · 9y expired
What this patent protects
The present invention relates to controlled-release C-type natriuretic peptide (CNP) agonists having an at least 5-fold longer degradation half-life in an in vitro neutral endopeptidase (NEP) degradation assay than the corresponding released CNP agonist, to pharmaceutical composi…
USPTO Abstract
The present invention relates to controlled-release C-type natriuretic peptide (CNP) agonists having an at least 5-fold longer degradation half-life in an in vitro neutral endopeptidase (NEP) degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.